The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits
Open accessAbstract
Empagliflozin (EMPA), an inhibitor of the renal sodium–glucose cotransporter (SGLT) 2, reduces the risk of cardiovascular death in patients with type 2 diabetes. The underlying mechanism of this effect is unknown. Elevated cardiac cytoplasmic Na + ([Na + ] c ) and Ca 2+ ([Ca 2+ ] c ) concentrations and decreased mitochondrial Ca 2+ concentration ([Ca 2+ ] m ) are drivers of heart failure and cardiac death. We therefore hypothesised that EMPA would directly modify [Na + ] c , [Ca 2+ ] c and [Ca 2+ ] m in cardiomyocytes. [Na + ] c, [Ca 2+ ] c , [Ca 2+ ] m and Na + /H + exchanger (NHE) activity were measured fluorometrically in isolated ventricular myocytes from rabbits and rats. An increase in extracellular glucose, from 5.5 mmol/l to 11 mmol/l, resulted in increased [Na + ] c and [Ca 2+ ] c levels. EMPA treatment directly inhibited NHE flux, caused a reduction in [Na + ] c and [Ca 2+ ] c and increased [Ca 2+ ] m . After pretreatment with the NHE inhibitor, Cariporide, these effects of EMPA were strongly reduced. EMPA also affected [Na + ] c and NHE flux in the absence of extracellular glucose. The glucose lowering kidney-targeted agent, EMPA, demonstrates direct cardiac effects by lowering myocardial [Na + ] c and [Ca 2+ ] c and enhancing [Ca 2+ ] m , through impairment of myocardial NHE flux, independent of SGLT2 activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Sgk1-Dependent Stimulation of Cardiac Na+/H+Exchanger Nhe1 by Dexamethasone
Voelkl, J., Pasham, V., Ahmed, M. S. E., Walker, B., Szteyn, K., Kuhl, D., Metzler, B., Alesutan, I., & Lang, F. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350120 · Cited by 857
Grempler, R., Thomas, L., Eckhardt, M., Himmelsbach, F., Sauer, A., Sharp, D. E., Bakker, R. A., Mark, M., Klein, T., & Eickelmann, P. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01517.x · Cited by 608
Kohlhaas, M., Liu, T., Knopp, A., Zeller, T., Ong, M. F., Böhm, M., O'Rourke, B., & Maack, C. (2010) · Circulation · doi:10.1161/circulationaha.109.914911 · Cited by 322
Intracellular Na + Concentration Is Elevated in Heart Failure But Na/K Pump Function Is Unchanged
Despa, S., Islam, M. A., Weber, C. R., Pogwizd, S. M., & Bers, D. M. (2002) · Circulation · doi:10.1161/01.cir.0000016701.85760.97 · Cited by 319
Vrhovac, I., Balen Eror, D., Klessen, D., Burger, C., Breljak, D., Kraus, O., Radović, N., Jadrijević, S., Aleksic, I., Walles, T., et al. (2015) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-014-1619-7 · Cited by 290
Liu, T., & O'Rourke, B. (2008) · Circulation Research · doi:10.1161/circresaha.108.175919 · Cited by 226
Baartscheer, A. (2003) · Cardiovascular Research · doi:10.1016/s0008-6363(02)00809-x · Cited by 203
Self-citationLiu, T., Takimoto, E., Dimaano, V. L., DeMazumder, D., Kettlewell, S., Smith, G., Sidor, A., Abraham, T. P., & O’Rourke, B. (2014) · Circulation Research · doi:10.1161/circresaha.115.303062 · Cited by 185
Marx, N., & McGuire, D. K. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw110 · Cited by 165
Pogwizd, S. M., Sipido, K. R., Verdonck, F., & Bers, D. M. (2003) · Cardiovascular Research · doi:10.1016/s0008-6363(02)00735-6 · Cited by 159
Heise, T., SEMAN, L. J., Macha, S., Jones, P., Marquart, A., Pinnetti, S., Woerle, H. J., & Dugi, K. A. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0030-2 · Cited by 137
Baartscheer, A., Schumacher, C. A., VANBORREN, M., Belterman, C. N. W., Coronel, R., Tobias Opthof, A., & Fiolet, J. W. T. (2004) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.09.024 · Cited by 129
Self-citationLambert, R., Srodulski, S. J., Peng, X., Margulies, K. B., Despa, F., & Despa, S. I. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.002183 · Cited by 119
Hamouda, N. N., Sydorenko, V., Qureshi, M. A., Alkaabi, J., Öz, M., & Howarth, F. C. (2014) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-014-2262-5 · Cited by 68
Cited by
Rangaswami, J., Bhalla, V., Blair, J. E. A., Chang, T. I., Costa, S., Lentine, K. L., Lerma, E. V., Mezue, K., Molitch, M., Mullens, W., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000664 · Cited by 1,409
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Verma, S., & McMurray, J. J. V. (2018) · Diabetologia · doi:10.1007/s00125-018-4670-7 · Cited by 999
Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors
Lopaschuk, G. D., & Verma, S. (2020) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2020.02.004 · Cited by 894
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
Cowie, M. R., & Fisher, M. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0406-8 · Cited by 784
Inzucchi, S. E., Zinman, B., Fitchett, D., Wanner, C., Ferrannini, E., Schumacher, M., Schmoor, C., Ohneberg, K., Johansen, O. E., George, J. T., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1096 · Cited by 740
“Moreover, only variablesmeasured during the trial could be examined, and in addition to the potential mediators we investigated, other variables such as reductions in glomerular hyperfiltration (35), reductions in arterial stiffness and vascular resistance (36), direct cardiac effects through reductions in myocardial…”
Background
Metadata
- Authors
- Baartscheer, A., Schumacher, C. A., Wüst, R. C. I., Fiolet, J. W. T., Stienen, G. J. M., Coronel, R., & Zuurbier, C. J.
- Venue
- Diabetologia
- Published
- 2016-10-17
- Volume
- 60
- Issue
- 3
- Pages
- 568-573
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2538443876
- Cited by
- 661
- References
- 15
- FWCI
- 33.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.